TKNO

+ Watchlist + Portfolio

Alpha Teknova, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $7.21
52-Week Range: $1.91 – $7.84
Market Cap: $375.82M
P/E (TTM): —
EPS (TTM): -0.31
Dividend Yield: —

Advanced Metrics

Price/Book: 5.45
PEG Ratio: —
Return on Equity: -24.19%
Return on Assets: -9.28%
Gross Margin: 34.60%
Operating Margin: -23.72%
Profit Margin: -38.37%
Current Ratio: 4.49
Debt/Equity: 0.44
Total Debt: $27.41M
Free Cash Flow: $-735.25K
Revenue Growth: 18.50%
Earnings Growth: —
Enterprise Value: $397.06M

TKNO Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$41.42M	$36.68M	$37.74M	$40.52M
Cost of Revenue	$23.94M	$26.39M	$30.51M	$27.08M
Gross Profit	$17.48M	$10.30M	$7.23M	$13.44M
Research & Development	$7.74M	$5.57M	$2.76M	$2.20M
Selling, General & Admin	$37.45M	$34.78M	$29.47M	$27.07M
Operating Expenses	$46.33M	$41.49M	$33.38M	$30.42M
Operating Income	-$28.86M	-$31.20M	-$26.15M	-$16.98M
EBITDA	-$25.69M	-$30.59M	-$19.57M	-$10.15M
Pretax Income	-$49.39M	-$37.08M	-$26.83M	-$17.20M
Income Tax	-$1.92M	-$298.00K	-$88.00K	$58.00K
Net Income	-$47.47M	-$36.78M	-$26.75M	-$17.26M
Diluted EPS	-1.69	-1.16	-0.57	-0.32
Diluted Shares	28.08M	31.82M	46.75M	53.48M

TKNO Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$42.24M	$28.48M	$3.71M	$5.91M
Receivables	$4.28M	$3.95M	$4.31M	$4.62M
Inventory	$12.25M	$11.59M	$6.80M	$7.05M
Current Assets	$61.14M	$45.66M	$42.78M	$34.51M
Total Assets	$152.26M	$128.59M	$118.77M	$103.58M
Current Liabilities	$10.88M	$8.88M	$11.21M	$7.54M
Long-Term Debt	$21.98M	$13.25M	$9.44M	$13.12M
Total Debt	$42.31M	$30.46M	$30.17M	$28.27M
Total Liabilities	$52.38M	$38.55M	$36.38M	$34.81M
Retained Earnings	-$55.01M	-$91.79M	-$118.53M	-$135.79M
Shareholders' Equity	$99.89M	$90.04M	$82.39M	$68.78M
Working Capital	$50.27M	$36.78M	$31.57M	$26.97M
Net Debt	—	—	$9.78M	$7.21M

TKNO Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$27.40M	-$18.81M	-$12.39M	-$8.65M
Capital Expenditure	-$28.15M	-$7.93M	-$1.13M	-$1.15M
Free Cash Flow	-$55.55M	-$26.75M	-$13.52M	-$9.79M
Depreciation & Amortisation	$3.17M	$5.66M	$6.58M	$6.34M
Stock-Based Compensation	$3.71M	$4.14M	$3.67M	$3.43M
Investing Cash Flow	-$28.15M	-$7.74M	-$27.27M	$10.70M
Financing Cash Flow	$10.27M	$12.80M	$14.89M	$151.00K
Net Change in Cash	-$45.28M	-$13.75M	-$24.78M	$2.20M

TKNO Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$9.79M	$10.29M	$10.45M	$9.98M	$11.08M
Cost of Revenue	$6.79M	$6.30M	$7.25M	$6.74M	$7.29M
Gross Profit	$3.01M	$3.98M	$3.21M	$3.24M	$3.78M
Research & Development	$552.00K	$581.00K	$542.00K	$522.00K	$609.00K
Selling, General & Admin	$7.13M	$6.50M	$6.39M	$7.04M	$7.19M
Operating Expenses	$7.97M	$7.37M	$7.22M	$7.85M	$8.08M
Operating Income	-$4.96M	-$3.39M	-$4.02M	-$4.61M	-$4.30M
EBITDA	-$2.90M	-$1.80M	-$2.43M	-$3.03M	-$2.71M
Pretax Income	-$4.62M	-$3.55M	-$4.21M	-$4.82M	-$4.51M
Income Tax	$22.00K	$19.00K	$79.00K	-$62.00K	$47.00K
Net Income	-$4.64M	-$3.57M	-$4.29M	-$4.76M	-$4.55M
Diluted EPS	-0.09	-0.07	-0.08	-0.09	-0.08
Diluted Shares	53.42M	53.45M	53.52M	53.54M	53.61M

TKNO Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$3.38M	$3.28M	$3.20M	$5.91M	$4.31M
Receivables	$5.62M	$5.14M	$5.13M	$4.62M	$5.67M
Inventory	$6.57M	$7.61M	$6.91M	$7.05M	$6.87M
Current Assets	$39.73M	$38.06M	$36.56M	$34.51M	$31.67M
Total Assets	$113.99M	$110.49M	$107.63M	$103.58M	$98.66M
Current Liabilities	$7.04M	$6.48M	$6.94M	$7.54M	$6.90M
Long-Term Debt	$12.99M	$13.03M	$13.08M	$13.12M	$13.17M
Total Debt	$29.34M	$28.97M	$28.98M	$28.27M	$27.83M
Total Liabilities	$35.39M	$34.43M	$34.98M	$34.81M	$33.73M
Retained Earnings	-$123.18M	-$126.75M	-$131.03M	-$135.79M	-$140.34M
Shareholders' Equity	$78.61M	$76.06M	$72.65M	$68.78M	$64.92M
Working Capital	$32.69M	$31.58M	$29.63M	$26.97M	$24.78M
Net Debt	$9.61M	$9.76M	$9.87M	$7.21M	$8.86M

TKNO Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$4.10M	-$2.10M	-$1.98M	-$462.00K	-$3.36M
Capital Expenditure	-$206.00K	-$207.00K	-$387.00K	-$348.00K	-$221.00K
Free Cash Flow	-$4.31M	-$2.31M	-$2.37M	-$810.00K	-$3.58M
Depreciation & Amortisation	$1.58M	$1.59M	$1.59M	$1.58M	$1.58M
Stock-Based Compensation	$852.00K	$950.00K	$850.00K	$777.00K	$695.00K
Investing Cash Flow	$3.82M	$2.03M	$1.64M	$3.21M	$1.84M
Financing Cash Flow	-$52.00K	-$28.00K	$268.00K	-$37.00K	-$88.00K
Share Repurchases	$0.00	$0.00	—	—	—
Net Change in Cash	-$331.00K	-$101.00K	-$72.00K	$2.71M	-$1.61M

Market Snapshot

About

Alpha Teknova, Inc. is a provider of critical reagents that enable the discovery, development, and production of biopharmaceutical products. The company manufactures molecular biology reagents, cell culture media, and custom products for life sciences research and clinical applications. Teknova serves pharmaceutical, biotech, academic, and government research organizations.